GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Why GSK (GSK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $33.81, marking a -0.82% move from the previous day.
GSK vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine
by Zacks Equity Research
Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DNL
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.29 in the latest trading session, marking a -0.98% move from the prior day.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.
GSK (GSK) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $36.27 in the latest trading session, marking a -0.3% move from the prior day.
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.
Company News for Jun 26, 2023
by Zacks Equity Research
Companies in The News Are: KMX, GS, SBUX, GSK.
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
by Zacks Equity Research
Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.62, moving -1.51% from the previous trading session.
GSK vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
GSK Announces Extension of FDA Review for Rare Blood Therapy
by Zacks Equity Research
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $34.64 in the latest trading session, marking a +0.73% move from the prior day.
FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody
by Zacks Equity Research
The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
by Zacks Equity Research
Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.36, moving -0.75% from the previous trading session.
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
by Zacks Equity Research
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $33.80, marking a +0.6% move from the previous day.
Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
by Zacks Equity Research
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.